logo-loader
viewCytoDyn Inc.

CytoDyn taps former Sarepta Therapeutics COO to its board of directors

Alan Timmins worked in a variety of executive positions over 16 years at Sarepta

Handshake
Timmins currently serves as the vice president for financial affairs at the University of Portland, a position he’s held for the past eight years

CytoDyn Inc (OTCMKTS:CYDY) announced Tuesday that Alan Timmins, former COO of the RNA-based therapeutics firm Sarepta Therapeutics Inc (NASDAQ:SRPT) has joined its board of directors as an independent director and chair of the audit committee. 

Timmins worked in a variety of executive positions over 16 years at Sarepta, including president, executive vice president, COO and CFO. He oversaw several of the life science technology company’s strategic financing and M&A efforts and helped grow it into the $9.5 billion market cap entity it is now.

He currently serves as the vice president for financial affairs at the University of Portland, a position he’s held for the past eight years. 

READ: CytoDyn files for breakthrough therapy status for leronlimab in metastatic triple-negative breast cancer

“Over the course of his career, Alan has led major growth initiatives — he was a key member of the team that built Sarepta Therapeutics into the company it is today, negotiating major commercial and governmental contracts, raising approximately $250 million, completing a strategic acquisition, and finalizing two out-licensing transactions,” CytoDyn Chairman Scott Kelly said in a statement. 

“Alan has accumulated an impressive array of strategic, financial and commercial achievements and has demonstrated his ability to be a successful and trusted leader. His breadth of experience will be instrumental to the audit committee and to CytoDyn as a whole,” Kelly added.

Earlier in his career, Timmins worked as a senior manager in the audit practice at PriceWaterhouseCoopers.

“I am pleased to be joining the CytoDyn board of directors at this important time in the Company’s development,” Timmins said. “Helping the company reach its considerable potential in the important therapeutic areas of HIV, cancer and immunology will be a worthy and challenging goal, and I look forward to assisting management and the board in reaching that goal.”

Concurrently, the company said farewell to resigning director Michael Klump.

“I would like to extend my sincerest gratitude to Michael Klump for serving on the board of directors of CytoDyn,” Kelly said. “Michael provided us with invaluable guidance and vision at a critical time for our company. Michael remains an ardent supporter of the science of CytoDyn and a significant investor. While Michael’s increasing business responsibilities drove his decision to step down from our board, I am thrilled that he will remain an advisor to both the CEO and chairman of the board.”

CytoDyn, based in Vancouver, Washington, is a late-stage biotechnology company developing leronlimab, a drug candidate with potential uses in multiple therapeutic treatments.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: CytoDyn Inc.

Price: 2.96 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.43 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

1 week, 4 days ago

3 min read